MIT in the media: For the future of tech, "Massachusetts can absolutely lead" MIT News. On June 9, The Boston Globe released its 2026 "Tech Power Players" list, recognizing 50 influential local leaders in technology and business across Massachusetts. The list includes eight MIT affiliates including President Sally Kornbluth, Prof. Daniela Rus (director of CSAIL), Prof. Regina Barzilay, Prof. Yet-Ming Chiang, Prof. Max Tegmark, Ana Bakshi (executive director of the Martin Trust Center for MIT Entrepreneurship), Katie Rae CEO and Managing Partner of Engine Ventures), and Senior Lecturer Brian Halligan, along with a number of MIT alumni. In addition to recognizing individual leaders, the Power Players coverage highlights MIT's research labs, its culture of innovation and entrepreneurship, industry connections, new AI initiatives, and the Institute's deep commitment to maintaining Massachusetts' technological leadership. "Massachusetts can absolutely lead in this next wave," says President Kornbluth, noting that the future is bright with burgeoning opportunities to advance technologies in fields from manufacturing, life and health sciences to quantum technologies and energy in service of Americans across the country. Advancing AI and entrepreneurship When it comes to AI, MIT is "working to drive artificial intelligence forward in sectors where the region is strongest, from biotechnology and robotics to defense and clean energy. It's also trying to broaden entrepreneurship through a 'dorm-to-startup' push, creating a pipeline of support services - from hack-a-thons to venture funding - to help students to start companies between classes," writes Robert Weisman for The Globe. Looking ahead, The Globe highlights how MIT aims to remain a central driver of AI advancement within higher ed. "President Sally Kornbluth is reinvigorating the school's support of the local innovation ecosystem," writes Aaron Pressman, noting how MIT is "unveiling new online classes dedicated to AI - with free entry-level classes for anyone - and encouraging more entrepreneurship on campus." MIT's free, online AI courses could help local tech leaders in their challenge "to ensure people, not only corporations, benefit from the technology," writes Pressman. And when it comes to applying AI technologies to real-world problems, MIT aims to ensure the greater Boston area remains a leader. "Some schools in Massachusetts, including MIT, are carving out a specialty in applied AI - sometimes called 'AI+X' - deploying the technology to help businesses, hospitals, and research institutions to supercharge productivity, innovation, and scientific breakthroughs," explains Weisman. Aman Narang '04, CEO of Toast, adds: "The superpower has always been the university system. The best thing Boston can do is keep these people around." MIT startups are a key driver of the region's entrepreneurial ecosystem. To ensure the greater Boston area remains a hub for innovators and to respond to growing student interest, MIT is looking to build upon its existing entrepreneurship resources for students, including the more than 150 courses and 85 centers and programs dedicated to fostering an entrepreneurial community. Additionally, President Sally Kornbluth and Provost Anantha Chandrakasan recently formed the Committee on Accelerating Translation and Entrepreneurship (CATE) to explore anew how the Institute can best support, remove barriers to, and accelerate the movement of ideas from MIT's research and innovative discoveries into new ventures. Further, reflecting on the optimism surrounding the Greater Boston tech scene, The Globe describes how applications for The Martin Trust Center for MIT Entrepreneurship's startup accelerator program have doubled from last year, and nearly one-fifth of MIT undergraduates - about 800 students - attended a recent startup career fair. Innovating change beyond MIT The simple worm could drive the future of AI. This might sound like a squishy premise, but that's the idea behind MIT startup Liquid AI, which is developing AI models inspired by the brain structure of a simple worm and could significantly reduce AI energy consumption. Liquid AI's models, "which can uncover financial fraud and pilot autonomous drones, require far less electricity to operate than large language models, saving energy and water, which is used to cool data centers," Pressman explains. The Globe highlights how Liquid AI recently signed a deal with Mercedes-Benz to incorporate its technology into the onboard systems of cars sold in North America. To power new AI technologies - and ensure Americans across the country can have reliable and affordable energy sources - researchers at MIT and a number of alumni are also turning their attention to the future of energy. In Prof. Yet-Ming Chiang's lab, researchers are developing batteries that can store more electricity over longer periods, creating "more opportunities for wind, solar, and other clean energy sources." Weisman highlights how "Chiang's lab and other MIT research centers are also working on innovations in microchips, critical minerals, fusion technology, and defense tech. All are examples of 'tough tech' projects combining science and engineering, which Chiang says 'are in the sweet spot of the Boston ecosystem.'" Soon, 80 MIT students will work as summer interns and employees at GE Vernova, thanks to the MIT-GE Vernova Climate and Energy Alliance, a collaboration aimed at advancing research and education that will accelerate the global energy transition. GE Vernova CEO Scott Strazik wanted his organization to "plug into the city's innovation culture," particularly the MIT campus and community. The company announced it would dedicate $50 million over five years to fund internships and research projects in which students and faculty work alongside GE Vernova engineers and technicians. The most promising area for the Greater Boston tech scene The Globe concludes by asking each Power Player what the most promising thing about the Greater Boston tech scene is right now. For Rus, the answer is: "talent. Boston has the best AI researchers in the world, and they're producing genuinely new ideas, not incremental ones," she explains. When it comes to realizing the potential of fusion energy, Bob Mumgaard SM '15, co-founder and CEO of Commonwealth Fusion Systems, explains that he couldn't have built the company anywhere but Massachusetts thanks to the region's expertise in engineering, designing, and manufacturing hardware and equipment and access to university researchers. "The ecosystem has the building blocks," says Mumgaard. "Massachusetts is the strongest in the nation in innovation in energy." President Kornbluth points to quantum. "There isn't a more important technological field right now than quantum science and technology, and the Boston area has the greatest concentration of quantum talent anywhere in the world," Kornbluth emphasizes. Loading...

Insilico Medicine releases 2025 annual results and advances AI drug discovery platform. March 29, 2026 at 4:15 PM - by MLQ Agent Key points. * Insilico Medicine will report 2025 financial results and business update on March 30, 202613. * Live conference calls in English and Mandarin set for 9:00 AM and 10:30 AM Beijing Time13. * Company advancing AI drug discovery with recent collaborations and platform enhancements57. * Past quarters show revenue declines averaging 21.7% annually alongside R&D investments6. * Recognized for AI platform impact, including Phase IIa results for rentosertib2. Insilico Medicine, a clinical-stage biotech firm using generative AI for drug discovery, plans to release its 2025 financial results and business update on March 30, 2026. The announcement follows a March 13 press release detailing conference calls in English and Mandarin13. Announcement details. Insilico Medicine announced on March 13, 2026, that it will report financial results for the year ended December 31, 2025, during live conference calls on March 30, 2026, Beijing Time. The English session starts at 9:00 AM Beijing Time, equivalent to 9:00 PM U.S. Eastern Time on March 29, 2026. The Mandarin session follows at 10:30 AM Beijing Time. Participants must pre-register via the provided Zoom link for the English call 134. Replays will be available on the company's website shortly after the calls 1. Recent business highlights. Insilico recently collaborated with Liquid AI, announced on March 8, 2026, focusing on AI advancements for drug discovery 57. In 2025, the company reported Phase IIa results for rentosertib, its first fully AI-discovered and designed small-molecule drug, which showed lung function stabilization or improvement in idiopathic pulmonary fibrosis patients with a favorable safety profile 2. The firm also completed Hong Kong's largest biotech IPO in 2025 and expanded partnerships with global pharmaceutical companies 2. Financial background. Historical data indicates revenues declining at an average annual rate of 21.7%, with net margins at -82.72% as of the last update 6. Quarterly figures for 2025 show revenues of $54 million in Q2 with a $44 million loss, following $70 million in Q1 with a $31 million loss. R&D expenses remained high, at $82 million in Q2 and $87 million in Q1 6. AI platform investment returns. Insilico Medicine's persistent revenue decline of 21.7% annually contrasts with robust R&D spending, reflecting heavy investment in its generative AI platform amid a challenging biotech funding environment 6. The company's recognition by Fast Company for clinical progress, particularly rentosertib's Phase IIa data, underscores the platform's potential to deliver real-world outcomes, even as losses widened 2. This pattern aligns with clinical-stage biotechs prioritizing pipeline advancement over near-term profitability. Strategic collaborations like the March 2026 Liquid AI milestone on private infrastructure highlight Insilico's focus on enhancing AI capabilities for drug discovery applications 57. The upcoming earnings call timing allows investors to assess how these developments offset revenue pressures and one-off costs, positioning the firm amid growing competition in AI-biotech integration. Earnings call pipeline updates. Investors await March 30 conference calls for insights into 2025 performance, including potential updates on rentosertib progression and new pipeline assets 13. Replays and website access will broaden reach, potentially influencing stock movements for ticker 3696.HK. Expanding partnerships could accelerate revenue through milestones or licensing 2 . Longer-term, Insilico's end-to-end AI approach may drive efficiencies in drug development timelines, building on 2025's clinical milestones. Sustained R&D amid revenue challenges will test capital allocation post-IPO, with focus on advancing preclinical and clinical programs toward commercialization 62. Market reception to earnings guidance will signal confidence in AI-driven biotech scalability. Further sources. Written with AI assistance, verified and edited by its team. Questions? Contact MLQ.ai.